Overview

Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer testis antigens. The clinical study for our ADP-A2M4 SPEAR T-cell is a phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity in certain patients with urothelial (bladder) cancers, melanoma, head and neck cancer, ovarian cancer, NSCLC, esophageal cancer, gastric cancers, synovial sarcoma, and Myxoid Round Cell Liposarcoma (MRCLS).

Please read below to learn more about the SPEARHEAD-1 trial, the ADP-A2M4 Phase 1 trial and the low-radiation sub-study.

Our Trials

SPEARHEAD-1 (ADP-A2M4)

This is a phase 2, open label, single arm clinical trial to evaluate the anti-tumor activity of ADP-A2M4 SPEAR T-cells in patients who are HLA-A*02 positive and have inoperable locally advanced synovial sarcoma or Myxoid Round Cell Liposarcoma (MRCLS) expressing MAGE-A4.

View Clinical Trial

ADP-A2M4 Phase 1 trial

This is a Phase I, open label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP-A2M4 therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial, head and neck, ovarian, non-small cell lung, esophageal, synovial sarcoma, Myxoid Round Cell Liposarcoma (MRCLS), and gastric cancers expressing MAGE-A4. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2M4. Further details are available via the link below.

View Clinical Trial

Low-radiation Sub-study (ADP-A2M4)

This is a phase 1, single-center substudy to characterize safety and tolerability and assess antitumor activity of low dose radiation in combination with ADP-A2M4 across multiple tumor types.  Up to 10 patients will be treated at MD Anderson Cancer Center. This is a sub-study of the ADP-A2M4 Phase 1 trial.

View Clinical Trial

Publications

Please visit our Publications page for more information on ADP-A2M4